Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Use of prothrombin complex concentrates for urgent reversal of dabigatran in the Emergency Department.

× No keyword cloud information.

11 in total

1. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation.

Authors: Agnès Lillo-Le Louët; Martine Wolf; Lilia Soufir; Arnaud Galbois; Anne-Sylvie Dumenil; Georges Offenstadt; Meyer-Michel Samama
Journal: Thromb Haemost Date: 2012-07-10 Impact factor: 5.249

2. Interpretation of point-of-care INR results in patients treated with dabigatran.

Authors: Joanne van Ryn; Lawrence Baruch; Andreas Clemens
Journal: Am J Med Date: 2012-02-03 Impact factor: 4.965

3. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

Authors: Ron Pisters; Deirdre A Lane; Robby Nieuwlaat; Cees B de Vos; Harry J G M Crijns; Gregory Y H Lip
Journal: Chest Date: 2010-03-18 Impact factor: 9.410

4. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate.

Authors: M D Lambourne; L J Eltringham-Smith; S Gataiance; D M Arnold; M A Crowther; W P Sheffield
Journal: J Thromb Haemost Date: 2012-09 Impact factor: 5.824

5. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model.

Authors: I Pragst; S H Zeitler; B Doerr; F J Kaspereit; E Herzog; G Dickneite; J van Ryn
Journal: J Thromb Haemost Date: 2012-09 Impact factor: 5.824

Review 6. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

Authors: Joanne van Ryn; Joachim Stangier; Sebastian Haertter; Karl-Heinz Liesenfeld; Wolfgang Wienen; Martin Feuring; Andreas Clemens
Journal: Thromb Haemost Date: 2010-03-29 Impact factor: 5.249

7. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.

Authors: Yong Bing Cao; Jun Dong Zhang; Hui Shen; Yuan Ying Jiang
Journal: Eur J Clin Pharmacol Date: 2010-09-02 Impact factor: 2.953

8. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.

Authors: Elise S Eerenberg; Pieter W Kamphuisen; Meertien K Sijpkens; Joost C Meijers; Harry R Buller; Marcel Levi
Journal: Circulation Date: 2011-09-06 Impact factor: 29.690

7. Use of 4-factor prothrombin complex concentrate in the treatment of a gastrointestinal hemorrhage complicated by dabigatran.

Authors: Terrance R McGovern; Justin J McNamee; Christopher Malabanan; Mohamed A Fouad; Nilesh Patel
Journal: Int J Emerg Med Date: 2015-04-15

Review 8. Management of bleeding in patients treated with direct oral anticoagulants.

Authors: Marcel Levi
Journal: Crit Care Date: 2016-08-20 Impact factor: 9.097

8 in total

Use of prothrombin complex concentrates for urgent reversal of dabigatran in the Emergency Department.

1. Life-threatening bleeding in four patients with an unusual excessive response to dabigatran: implications for emergency surgery and resuscitation.

2. Interpretation of point-of-care INR results in patients treated with dabigatran.

3. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.

4. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilate.

5. Reversal of dabigatran anticoagulation by prothrombin complex concentrate (Beriplex P/N) in a rabbit model.

Review 6. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.

7. Rivaroxaban versus enoxaparin for thromboprophylaxis after total hip or knee arthroplasty: a meta-analysis of randomized controlled trials.

8. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.

9. Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

10. Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety profile.

Review 1. The impact of prothrombin complex concentrates when treating DOAC-associated bleeding: a review.

Review 2. Reversal of anticoagulant effects in patients with intracerebral hemorrhage.

3. Management of new oral anticoagulants related life threatening or major bleedings in real life: a brief report.

Review 4. Direct Oral Anticoagulants in Emergency Trauma Admissions.

Review 5. New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty.

6. Updates in the perioperative and emergency management of non-vitamin K antagonist oral anticoagulants.

7. Use of 4-factor prothrombin complex concentrate in the treatment of a gastrointestinal hemorrhage complicated by dabigatran.

Review 8. Management of bleeding in patients treated with direct oral anticoagulants.